Netupitant/palonosetron

Netupitant/palonosetron, sold under the brand name Akynzeo, is a fixed-dose combination medication for prevention of acute and delayed chemotherapy-induced nausea and vomiting.[4][5] It is marketed and distributed by Helsinn Therapeutics. Netupitant is an NK1 receptor antagonist and palonosetron is a 5-HT3 receptor antagonist.[6]

Netupitant/palonosetron
Combination of
NetupitantNK1 receptor antagonist
Palonosetron5-HT3 receptor antagonist
Clinical data
Trade namesAkynzeo
AHFS/Drugs.comMonograph
MedlinePlusa614053
License data
Pregnancy
category
    Routes of
    administration    		By mouth, intravenous
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)
    • UK: POM (Prescription only) [3]
    • US: ℞-only
    • In general: ℞ (Prescription only)
    Identifiers
    KEGG

    The capsules contain netupitant and palonosetron hydrochloride. The intravenous version is a combination of fosnetupitant chloride hydrochloride and palonosetron hydrochloride.[7][4]

    Contraindications

    Netupitant/palonosetron may be contraindicated during pregnancy.[8][1][2]

    Adverse effects

    The most common side effects include headache, weakness, fatigue, upset stomach, constipation, and skin redness.[4] The overall profile of adverse effects is comparable to that of palonosetron (see Palonosetron#Adverse effects); no common adverse effects can be attributed to netupitant.[8]

    Interactions
    Further information: Netupitant § Interactions, and Palonosetron § Interactions

    Pharmacology
    Further information: Netupitant § Pharmacology, and Palonosetron § Pharmacology

    History

    Netupitant/palonosetron was approved for use in the United States in October 2014.[9] It was approved for use in the European Union in May 2015.[10] The intravenous version was approved in the United States in April 2018.[11][7]

    References
    1. "Netupitant / palonosetron (Akynzeo) Use During Pregnancy". Drugs.com. 22 October 2018. Retrieved 19 March 2020.
    2. "Fosnetupitant / palonosetron (Akynzeo for Injection) Use During Pregnancy". Drugs.com. 22 October 2018. Retrieved 19 March 2020.
    3. "Akynzeo 300 mg/0.5 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 11 February 2020. Retrieved 19 March 2020.
    4. "Akynzeo- netupitant and palonosetron capsule Akynzeo- fosnetupitant and palonosetron injection". DailyMed. 28 May 2020. Retrieved 18 July 2020.
    5. "FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy". U.S. Food and Drug Administration (FDA). 10 October 2014. Archived from the original on 1 February 2017. Retrieved 16 December 2019.
    6. "Akynzeo: Summary of Product Characteristics" (PDF). European Medicines Agency. Retrieved 12 July 2016.
    7. "Drug Trials Snapshots: Akynzeo". U.S. Food and Drug Administration (FDA). 11 May 2018. Retrieved 19 March 2020.
    8. Haberfeld, H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Akynzeo 300 mg / 0,5 mg Hartkapseln.
    9. "Drug Approval Package: Akynzeo (Netupitant and Palonosetron) Capsules NDA #205718". U.S. Food and Drug Administration (FDA). 7 November 2014. Retrieved 19 March 2020.
    10. "Akynzeo EPAR". European Medicines Agency (EMA). 19 March 2020. Retrieved 19 March 2020.
    11. "Drug Approval Package: Akynzeo (fosnetupitant and palonosetron) Injection". U.S. Food and Drug Administration (FDA). 31 May 2018. Retrieved 19 March 2020.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.